GlassScriptPhysician profile
Jasbir Dhawan
NPI 1063458230
$244,639.03
in general payments reported to CMS, 2019-2025
63 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105K · 2020: $49K · 2021: $17K · 2022: $34K · 2023: $12K · 2024: $8,277 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $9,134 · Travel and Lodging: $2,355 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,150.31 |
| Food and Beverage | $9,133.78 |
| Travel and Lodging | $2,354.68 |
| Education | $267.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $155,778.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $32,964.84 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $14,802.10 | 2019-2025 | Farxiga |
| Janssen Pharmaceuticals, INC | $10,606.48 | 2019-2020 | |
| Lilly USA, LLC | $8,975.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Mannkind Corporation | $4,002.54 | 2019-2025 | Afrezza |
| Medtronic, INC. | $1,872.97 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Insulet Corporation | $1,543.55 | 2019-2025 | Omnipod |
| Amgen INC. | $1,447.72 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,350.98 | 2019-2025 | Jardiance, Synjardy |
| Antares Pharma, INC. | $873.08 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Sanofi-Aventis U.S. LLC | $785.72 | 2019-2025 | |
| Abbott Laboratories | $784.18 | 2019-2025 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $700.71 | 2019-2025 | Unithroid |
| Cequr Corporation | $693.29 | 2022-2024 | Cequr Simplicity |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $676.45 | 2019-2025 | Korlym |
| Amarin Pharma, INC. | $616.65 | 2019-2022 | |
| Radius Health, INC. | $539.37 | 2019-2025 | Tymlos |
| Dexcom, INC. | $518.33 | 2019-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $472.60 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Valeritas, INC. | $395.74 | 2019 | |
| Ibsa Pharma INC. | $374.67 | 2019-2025 | Licart, Tirosint, Flector |
| Merck Sharp & Dohme LLC | $352.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.07 | 2022-2025 | |
| Abbvie INC. | $282.04 | 2019-2025 | Synthroid |
| Zealand Pharma US, INC. | $277.45 | 2020-2022 | |
| Esperion Therapeutics, INC. | $273.66 | 2020-2025 | Nexletol |
| Currax Pharmaceuticals LLC | $175.01 | 2021-2024 | Contrave, Onzetra Xsail |
| Endo Pharmaceuticals INC. | $155.29 | 2019-2021 | |
| Astellas Pharma US INC | $147.84 | 2023 | Veozah |
| Alexion Pharmaceuticals, INC. | $139.76 | 2019-2024 | Strensiq |
| Tolmar, INC. | $138.08 | 2023-2025 | Jatenzo |
| Clarus Therapeutics INC. | $130.82 | 2021 | |
| Amryt Pharma Holdings LTD | $99.86 | 2022 | |
| Madrigal Pharmaceuticals | $98.22 | 2025 | Rezdiffra |
| Recordati_rare_diseases_inc. | $91.96 | 2023-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $91.90 | 2025 | Yorvipath |
| Becton, Dickinson and Company | $90.72 | 2019-2022 | |
| Acella Pharmaceuticals, LLC | $89.47 | 2021-2025 | NP Thyroid 60 |
| Vistapharm, INC. | $79.56 | 2021 | |
| Alfasigma USA, INC. | $76.08 | 2020-2021 | |
| Ascensia Diabetes Care US INC. | $68.77 | 2021-2023 | |
| Companion Medical, INC. | $59.90 | 2019-2020 | |
| Eisai INC. | $57.41 | 2019 | |
| Pfizer INC. | $53.33 | 2019-2023 | |
| Kvk-Tech, INC. | $52.58 | 2019 | |
| Avvisto Therapeutics, LLC | $50.33 | 2024-2025 | Cycloset |
| Sequel Med Tech, LLC | $49.94 | 2025 | Twiist |
| Verity Pharmaceuticals INC. | $41.30 | 2025 | Tlando |
| Halozyme INC | $38.95 | 2023 | |
| Beta Bionics, INC. | $36.65 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Neurocrine Biosciences, INC. | $34.54 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $33.41 | 2020-2022 | |
| Boston Scientific Corporation | $29.84 | 2019 | |
| Kyowa Kirin, INC. | $25.48 | 2023 | Crysvita |
| Globus Medical, INC. | $24.72 | 2025 | Omnia |
| Takeda Pharmaceuticals U.S.A., INC. | $23.29 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.57 | 2021 | |
| Medtronic Minimed, INC. | $18.61 | 2019 | |
| Vivus LLC | $17.00 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.31 | 2023 | Adthyza |
| Nalpropion Pharmaceuticals LLC | $15.06 | 2019 | |
| Althera Pharmaceuticals LLC | $2.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasbir Dhawan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.